Multiple phase II and III studies have shown that ipilimumab and nivolumab are active in advanced melanoma and that the combination therapies involving PD-1 or CTLA-4 inhibitors presented a superior efficacy when compared to the individual monotherapies (50–53). Here, CTLA4 is linked to melanoma.